This Biotech Stock 700%: Top Holding After $9.3M Sale
A biotech stock that surged 700% remains a cornerstone of many portfolios even after a sizable last-quarter sale by a...
Find out when rewards points are truly worth it. Maximize your benefits and learn how to save more on your travels.
15,541 articlesA biotech stock that surged 700% remains a cornerstone of many portfolios even after a sizable last-quarter sale by a...
It's been years since the 2020 market panic, and the S&P 500 has staged a powerful recovery. This article breaks down...
A major institutional move signals a shift in risk tolerance and strategy. Learn what arcus capital scales back means...
May could mark a turning point for investors eyeing the clean energy revival. This article breaks down two nuclear en...
Investors are debating whether Microsoft stock is a steal right now. This deep-dive breaks down valuation, cash flow,...
Headline-grabbing insider sales can feel alarming, but the true driver of stock performance is deal flow. Learn to se...
Investors are watching Duluth Trading closely as the Q1 2026 earnings cycle begins. This in-depth look breaks down wh...
Choosing between broad tech exposure and a semiconductor focus can shape your portfolio’s risk and return. This guide...
Oruka stock has surged dramatically, propelled by momentum and speculation. A substantial insider sale adds another l...
Nvidia’s shares lag the broader chip rally even as demand for AI accelerates, prompting questions about earnings timi...
Cellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
Gold ETFs still track spot prices, but GLD's 0.40% expense ratio is quietly eroding long-term gains. Through mid-2026...